Oxygen Biotherapeutics Video Library
News & Events
Oxygen Biotherapeutics Names Col. Charles L. Pamplin III, M.D., Chief Medical Officer - Expertise in the development of numerous commercialized drugs and his military background to support Company’s development path -
MORRISVILLE, N.C.--(BUSINESS WIRE)--May. 21, 2013-- Oxygen Biotherapeutics, Inc. (“OBI”) (NASDAQ: OXBT), today announced Col. (ret.) Charles L. Pamplin III, M.D., was appointed to the position of Chief Medical Officer effective May 20. In this position, he reports to the Chief Executive Officer. Dr. Pamplin will be implementing the Company’s strategic clinical development plan. His responsibilities will include overseeing Clinical Development of Oxycyte, OBI’s lead product candidate currently in Phase IIb clinical trials in Israel and Switzerland for traumatic brain injury, as well as preclinical studies here in the U.S. more..
Oxygen, Elastin, and Collagen – Dr. Gerald Klein talks about why oxygen is important for skin.
Oxycyte and Decompression Sickness – Dr. Gerald Klein explains Decompression Sickness.
Oxycyte Ischemia – Dr. Gerald Klein explains ischemia
Oxycyte Traumatic Brain Injury – Dr. Gerald Klein explains What is severe traumatic brain injury? Can Oxycyte help?